Dermatology

Sharing data and a personal recommendation can make a difference in a patient’s life

Bimekizumab-bkzx (Bimzelx; Union Chimique Belge) is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin (IL)-17A and IL-17F.

It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.

The efficacy data are consistent with other phase 3 studies, reinforcing lebrikizumab's potential as a first-line treatment across a range of skin tones.

To date, this is the only targeted therapy indicated for the treatment of generalized pustular psoriasis.

The agency will focus on collaboration to protect public health; advancing regulatory approaches; developing standards, guidelines, and best practices; and supporting research that evaluates and monitors AI performance.

Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.

The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.

The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

Topical niacinamide stabilizes the skin's outer barrier, reducing water loss and improving moisture levels in the epidermis.

With a wide array of OTC products, pharmacists can help patients select the right regimen

Treating older patients requires a greater focus on treating their AD without exacerbating their comorbidities.

OTC products can help winter-proof skin and prevent dermatological flare-ups

Berdazimer topical gel, 10.3% (Zelsuvmi; Ligand Pharmaceuticals Inc) has been approved for the treatment of molluscum contagiosum in individuals aged 1 year and older.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Biologics for plaque psoriasis has been associated with an atopic dermatitis phenotype, paradoxical eczema, but the risk factors are not well known.

Acne is one of the most common conditions, with about 50 million Americans dealing with acne annually.

It's key for clinicians to optimize therapy prior to systemic agents.

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

Pharmacists should educate patients on proper application of OTC hair loss products and help identify any medications that may be contributing.

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.

A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.